問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Digestive System Department

更新時間：2023-09-19

莊萬龍Chuang, Wan-Long
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 3 個月

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊萬龍

List

160Cases

2025-02-03 - 2029-12-23

Not yet recruiting
A phase 3 randomized, double-blind, placebo-controlled trial compared TPST-1120 with Atezolizumab plus Bevacizumab to placebo plus Atezolizumab plus Bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma (HCC) who had not received systemic therapy.

  • Condition/Disease

    ● Overall survival (OS) is defined as the time elapsed from random assignment until death from any cause.

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2025-09-23 - 2028-02-13

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    膜衣錠 膜衣錠

Participate Sites
8Sites

Recruiting8Sites

2025-12-01 - 2032-08-02

Others

Active
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  • Condition/Disease

    Primary Biliary Cholangitis

  • Test Drug

    膠囊劑

Participate Sites
7Sites

Not yet recruiting7Sites

2015-04-01 - 2020-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
20Sites

Terminated19Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2019-11-01 - 2028-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2009-02-01 - 2010-11-01

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-10-01 - 2010-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-12-01 - 2011-07-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-08-01 - 2027-02-28

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2026-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB